ArticleBMC cancer2024

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis.

Xiewei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.